SUBSCRIBE
SUBSCRIBE
News   Drug Development

Array BioPharma, Inc. Initiates Phase 1 Clinical Trial for MEK Inhibitor ARRY-300

January 9, 2009 | 
1 min read

BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) has initiated dosing in healthy volunteers in a Phase 1 clinical trial with ARRY-300, a targeted small molecule MEK inhibitor.

Clinical research Phase I
MORE ON THIS TOPIC
vintage textured collage with symbols of New York City
Tariffs
Biotech’s Next Phase Will Be All-American: Pitchbook
April 17, 2025
 · 
2 min read
 · 
Annalee Armstrong
Closeup of businessman give money to robot. Man pass banknote bribe to robotic assistant. AI and technology. Vector illustration.
Artificial intelligence
Sanofi Bets More Than $1.8 Billion in Biobucks on AI-Developed Bispecifics
April 17, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Profit and Money Concept, Financial and Business Graph
GLP-1
Lilly Skyrockets on ‘Injectable-Like Efficacy’ for Oral GLP-1 in Phase III Diabetes Trial
April 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Lungs health and pulmonology as a respiratory medicine conept for pulmonary science and lung cancer or respiration disease and bronchi breathing or asthma symbol in a 3D illustration style.
Clinical research
Sanofi’s $1.4B Kymab Bet Falters as Asthma Drug Stumbles in Phase II
April 16, 2025
 · 
2 min read
 · 
Tristan Manalac